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a b s t r a c t
An expedient synthesis of orthogonally protected lysinoalanine has been developed. We have prepared a
novel Garner’s aldehyde derivative bearing an Aloc group; reductive amination of this aldehyde with
Fmoc-Lys-OPMB gave the lysinoalanine skeleton. This was then transformed into an orthogonally pro-
tected lysinoalanine derivative suitable for the synthesis of side-chain bridged cyclic peptides by solid
phase peptide synthesis methods.
 2010 Elsevier Ltd. All rights reserved.
The unusual bis-amino acid lysinoalanine (1) is a key compo-
nent of the cinnamycin group of type B lantibiotics. The lantibiotics
are a family of highly complex peptide antibiotics, produced by
Gram-positive bacteria.1 These peptides contain one or more of
the unusual bis-amino acids lanthionine (Lan) and methyllanthio-
nine (MeLan). Peptides incorporating these thioether analogues of
cystine have multiple cyclic structures with thioether bridges
between amino acid side chains. In the cinnamycin family of lanti-
biotics, the lanthionine bridges are nested, resulting in a very com-
pact structure. In addition, these peptides contain one
lysinoalanine residue, which forms an additional bridge between
the C-terminus and the sixth residue (Fig. 1). In recent years there
has been intense interest in the lantibiotics, arising from their
intriguing biochemical properties.1,2 Cinnamycin has antibacterial
activity,2 and also inhibits phospholipase A2 by speciﬁcally recogn-
ising and binding to phosphatidylethanolamine (PE) and lysophos-
phatidylethanolamine (lysoPE).2 It therefore has potential as a lead
structure for the development of both antiinﬂammatory and anti-
bacterial drugs. Hence, there is a need to synthesise cinnamycin,
and simpliﬁed subunits and analogues, in order to develop the lead
structure.
Lysinoalanine (1) has also been isolated from proteins that have
undergone treatment with alkali.3 In both cases, lysinoalanine is
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Figure 1. Cinnamycin and component bis-amino acids.
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believed to be formed from the addition of the e-NH2 group of ly-
sine to a dehydroalanine residue, which in turn is formed via dehy-
dration of serine. In the cinnamycin family of lantibiotics both
steps are probably catalysed by one or more enzymes to give a sin-
gle diastereoisomeric product, although these enzymes have not
yet been isolated or characterised.1b Conversely, in proteins that
have been treated with alkali a mixture of diastereoisomers is
formed.3
We recently developed a powerful approach to the on-resin
synthesis of lanthionine-bridged peptides.4 This requires the prep-
aration of differentially protected lanthionine, in which one pair of
amino and carboxy moieties bear allyloxycarbonyl (Aloc) and allyl
protecting groups, and the other pair is protected with an Fmoc
group only. As the allyl and Aloc groups are orthogonal to both
the transient (Fmoc) and permanent (Boc) protecting groups used
in conventional solid-phase peptide synthesis, this enabled us to
incorporate these protected lanthionines into linear peptides, fol-
lowed by selective deprotection of the allyl and Aloc groups, cycli-
sation and further chain extension, to give analogues of ring C of
the lantibiotic nisin.4 Vederas and co-workers have used this
approach in the ﬁrst total synthesis of the lantibiotic bis(desmeth-
yl) lacticin 3147 A25 and of lactocin S.6 Other groups have also pub-
lished syntheses of differentially protected lanthionine derivatives
suitable for solid-phase peptide synthesis.7 We have also synthes-
ised differentially protected (2S,9R)-diaminodecanedioic acid and
used similar methodology to incorporate this in peptides to give
aliphatic bridges between amino acid side chains,8 whilst Vederas
and co-workers have synthesised meso-3-(oxa)diaminopimelic
acid and used this to make an oxa-analogue of lacticin A2.9
In order to use this methodology to synthesise lantibiotics such
as cinnamycin, a reliable synthesis of the correct diastereoisomer
of the protected lysinoalanine 2 was required. As with the pro-
tected lanthionine derivatives used in our earlier work,4 we
required the lysine-derived moiety to be protected with Fmoc/
PMB groups, the serine-derived moiety to be protected with
Aloc/allyl groups, which would be selectively removed prior to
on-resin peptide cyclisation and the secondary amine to be pro-
tected with a Boc group (compatible with other side-chain protect-
ing groups in the peptide). Previously published syntheses
followed biomimetic routes3 via Michael addition of the e-NH2
group of lysine to dehydroalanine. These synthetic routes generally
afforded the unprotected bis-amino acid, which would be chal-
lenging to convert into the required differentially protected amino
acid. In addition, synthesising heteroatom-bridged bis-amino acids
by Michael addition to dehydroalanine derivatives leads to a mix-
ture of diastereoisomers at the alanine-derived chiral centre.3,10
We therefore needed to develop a new route that would afford a
differentially protected bis-amino acid and would also preserve
the chiral integrity of the two a-amino acid centres.
We envisaged that the key coupling step could be carried out by
reductive amination between a suitably protected lysine derivative
3 and Garner’s aldehyde (Scheme 1) to form the secondary amine
bridge. In order to minimise the number of protecting group
manipulations after this step, we required Aloc-protected Garner’s
aldehyde, 4. Although Boc-Garner’s aldehyde11,12 is well-known
and widely used, and the Cbz- and COOMe analogues have been
described,13 the Aloc-protected version had not been previously
prepared. As we required the (R)-aldehyde for our synthesis, we
elected to start from D-serine. (The alternative route to (R)-Garner’s
aldehyde from L-methionine11c was not investigated, as the ﬁnal
step of this synthesis involves the oxidative cleavage of a double
bond, which would not be compatible with the Aloc or allyl
groups.) Aloc-D-Ser-OMe was prepared by esteriﬁcation followed
by Aloc protection, and converted into the oxazolidine 5 using
2,2-dimethoxypropane with BF3OEt2 as the catalyst.14 This was
then followed by LiBH4 reduction15 to afford alcohol 6. Finally,
aldehyde 4 was prepared via a modiﬁed Swern oxidation using
diisopropylamine.16,17 The entire procedure could be expediently
carried out in 52% overall yield on 0.5–5 g scales.
Fmoc-Lys-OPMB 3 was readily prepared from the available
Fmoc-Lys(Mtt)-OH in two steps (Scheme 2). Reductive amination18
with 4 afforded the secondary amine 7 in moderate yield after
puriﬁcation. However, this material turned out to be unstable, with
loss of the Fmoc group observed even during storage at 20 C,
which we attribute to intramolecular deprotection by the second-
ary amino group. A two-step procedure, in which 7 was isolated
and then immediately protected with di-tert-butyl dicarbonate,
was more satisfactory and gave 8 in good yield. Selective deprotec-
tion of the N,O-isopropylidene group in the presence of the acid-
labile PMB and Boc groups required careful optimisation. Treat-
ment with 80% acetic acid at room temperature,19 or BiBr3,20 gave
no reaction, whilst with 1 M HCl21 partial PMB cleavage was
observed in addition to removal of the N,O-isopropylidene. Selec-
tive deprotection was ﬁnally achieved with p-toluenesulfonic acid
to give the alcohol 9.
The presence of the acid- and base-labile protecting groups, to-
gether with the double bonds in the Aloc and allyl groups, meant
that a very mild method for oxidation of 9 into the carboxylic acid
was also required. TEMPO/NaOCl oxidation was unsuccessful,
probably due to addition of hypochloric acid to the allylic groups.22
TPAP/NMO oxidation23 was likewise unsuccessful, with only the
aldehyde being formed as judged by mass spectrometry. However,
with TEMPO/bis[(acetoxy)iodo]benzene (BAIB)24 good conversion
into the carboxylic acid was seen without any removal of the labile
protecting groups or oxidation of the allylic groups. Both this com-
pound and 9 proved problematic to purify, resulting in low isolated
yields. It was therefore expedient to carry out both the deprotec-
tion and oxidation steps without puriﬁcation, and thence to form
the allyl ester 2 by reaction with allyl bromide and Cs2CO3.
Reductive amination of Boc-protected Garner’s aldehyde has
previously been described25 and it has been demonstrated that
the stereochemical integrity of the chiral centre is not compro-
mised during the reaction. Likewise, imine derivatives of Garner’s
aldehyde have been successfully prepared and reacted with carbon
nucleophiles.26 We did not, therefore, anticipate problems with the
reductive amination of 4 to give 8. Although doubling of some
peaks in the NMR spectra of 8 and 2 were seen at 25 C; on heating
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Scheme 1. Synthesis of Aloc-Garner’s aldehyde.
6382 C. Körner et al. / Tetrahedron Letters 51 (2010) 6381–6383
Author's personal copy
to 75 C these resolved to give single peaks (Supplementary data),
as was seen with the aldehyde 4, clearly indicating that a single
diastereoisomer of the protected lysinoalanine derivative had been
formed.
In summary, we have developed a synthetic route to lysinoala-
nine via the reductive amination of a novel Aloc-protected Garner’s
aldehyde derivative. The synthetic strategy ensures that the two
carboxylic acid groups, and three amino groups, remain differenti-
ated throughout, allowing the preparation of an orthogonally pro-
tected bis-amino acid. We envisage that this will be useful in the
solid-phase preparation of a range of constrained peptides.
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